Scientists in Switzerland have reported a significant discovery in the realm of antibiotics, unveiling a novel class that proves effective against drug-resistant bacteria, particularly the formidable Acinetobacter baumannii.
This newly identified antibiotic, named zosurabalpin, operates by obstructing the action of lipopolysaccharide (LPS), a bacterial molecule crucial for forming the outer membrane that shields Acinetobacter baumannii. This bacterium falls under the category of “gram-negative” bacteria, known for their resistance to a majority of antibiotics and other medications.
Acinetobacter baumannii is known to cause infections in various body parts, such as the blood, lungs, and urinary tract, presenting a significant challenge in healthcare. In animal trials, zosurabalpin demonstrated effectiveness in eliminating drug-resistant strains of Acinetobacter.
The research carried out at Roche Pharma Research & Early Development in Switzerland, was published in the journal Nature on January 3rd, marking a notable advancement in the fight against drug-resistant bacteria.
